Evolution of the Average Target: Ipsen

Evolution of the Average Target - Ipsen

Evolution of the Target Price: Ipsen

Evolution of the Target Price - Ipsen

Changes in Analyst Recommendations: Ipsen

1ec76abaa.6EZfl4Hlag4GYNqc6l8vUmk_mdRGamiNlqhK9fprr44.onEe_c6VKDtINarNpmloHQ9z9J0oXj_LxvcAjKMJ3tbfMm3P66MAd1MUsQ~fc07eec3dbfbf19962033e6c44d1b000
10-22 Ipsen: Better-than-expected Q3 overshadowed by 2027 Somatuline erosion and arbitration risk Alphavalue
09-18 AlphaValue/Baader Europe Ups Price Target, Forecasts for Ipsen on 'Solid' H1 Performance MT
09-17 Ipsen: Incorporating solid H1 operational performance + guidance upgrade Alphavalue
09-17 Ipsen extends its pullback despite AlphaValue Zonebourse
08-20 Cancer vaccines finally garner the spotlight Alphavalue
08-17 Kepler Cheuvreux Boosts Ipsen PT, Maintains Hold Rating MT
08-03 Jefferies Downgrades Ipsen to Underperform, Boosts PT MT
07-30 Ipsen: Another quarterly beat; 2026 guidance upgraded Alphavalue
07-14 Where would AI lead Pharma in the long run? Alphavalue
07-07 AlphaValue/Baader Europe Cuts Ipsen Price Target Amid Future Patent Expiries, Mid-term Risks MT
07-06 Ipsen: Reassessing mid-term risks Alphavalue
07-01 AlphaValue/Baader Europe Downgrades Ipsen to Add, Lifts PT MT
07-01 Oddo BHF still neutral on Ipsen after a new acquisition Zonebourse
06-30 Ipsen Extends Its Rally, Backed by Oddo BHF Zonebourse
06-05 HC Wainwright Starts Ipsen Coverage with Buy Rating MT
05-28 Ipsen Price Target, Estimates Up as AlphaValue/Baader Europe Notes Upcoming Data Readouts, Product Mix MT
05-27 Ipsen: Beneficiary of favourable product mix and imminent readouts Alphavalue
04-24 Profit-taking hits Ipsen despite UBS price target hike Zonebourse
04-24 Ipsen: Opened the year with encouraging traction Alphavalue
04-14 Deutsche Bank raises price target on Ipsen Zonebourse
03-16 BNP Paribas Upgrades Ipsen to Neutral, Boosts PT MT
03-10 CIC Corporate & Institutional Banking Upgrades Ipsen to Buy, Boosts PT MT
02-13 Ipsen Remains in the Green with UBS Support Zonebourse
02-12 Ipsen: Markets applaud strong finish to 2025 and better-than-expected 2026 outlook Alphavalue
01-14 Ipsen, Top Gainer on the SBF 120 and SRD at Wednesday, January 14, 2026 Close Zonebourse

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+7.73%
+4.27%
+4.92%
-0.68%
-2.56%
+13.62%
-2.85%
+22.47%
-10.64%
+0.95%
Average +3.72%
Weighted average by Cap. +3.55%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
152.50EUR
Average target price
163.21EUR
Spread / Average Target
+7.03%
High Price Target
235.00EUR
Spread / Highest target
+54.10%
Low Price Target
130.00EUR
Spread / Lowest Target
-14.75%

Analyst Consensus Detail

Analyst consensus - Ipsen

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Ipsen
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Ipsen